MabCure (OTCPK:MBCI) - Stock Price, News & Analysis

MBCI Stock Overview

MBCI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($781)

Latest financial reports are more than a year old

Shares are highly illiquid

MabCure, Inc. Competitors

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

ObsEva

OTCPK:OBSE.F

US$117.0

DermTech

OTCPK:DMTK.Q

US$35.0

Price History & Performance

Summary of all time highs, changes and price drops for MabCure
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0011
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
33 Year Change	-99.97%
5 Year Change	-99.83%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	MBCI	US Biotechs	US Market
7D	0%	4.3%	1.6%
1Y	n/a	18.8%	32.3%

Return vs Industry: Insufficient data to determine how MBCI performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MBCI performed against the US Market.

Price Volatility

Is MBCI's price volatile compared to industry and market?
MBCI volatility
MBCI Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: MBCI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine MBCI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	n/a	Jehu Thomas Hand	n/a

MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan.

MabCure, Inc. Fundamentals Summary

How do MabCure's earnings and revenue compare to its market cap?
MBCI fundamental statistics
Market cap	US$781.00
Earnings (TTM)	-US$12.26m
Revenue (TTM)	US$500.00k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is MBCI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MBCI income statement (TTM)
Revenue	US$500.00k
Cost of Revenue	US$0
Gross Profit	US$500.00k
Other Expenses	US$12.76m
Earnings	-US$12.26m

Last Reported Earnings

Dec 31, 2011

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did MBCI perform over the long term?

See historical performance and comparison